BAMLET belongs to the family of drug candidates that includes HAMLET and Alpha1H and was developed by Lund University. Hamlet Pharma owns the patent rights to BAMLET but has not conducted its own research or development of the product. The intention is to ensure access to available research and development around BAMLET through cooperation agreements.
BAMLET, which is made from cow’s milk, is, like HAMLET, a substance that effectively kills cancer cells and has shown effects against growing tumor tissue, especially for colon cancer. Hamlet Pharma is therefore driving the development of BAMLET (bovine α-lactalbumin made lethal to tumor cells) as a future drug against cancer. The company intends to establish production of BAMLET primarily for clinical studies of the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.